Related Experiment Video
Updated: May 3, 2026
16:10
A TIRF Microscopy Technique for Real-time, Simultaneous Imaging of the TCR and its Associated Signaling Proteins
Published on: March 22, 2012
25.3K
CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants
J Trebing1, M El-Mesery2, V Schäfer1
1Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Röntgenring 11, Würzburg, Germany.
Cell Death & Disease
|February 1, 2014
Summary
Researchers developed novel fusion proteins targeting CD70-expressing tumors. These proteins combine tumor cell death induction with inhibition of CD70-CD27 interactions, offering a promising strategy for cancer therapy.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- CD70-expressing tumors present a therapeutic target.
- CD70 antibodies can inhibit CD27 stimulation.
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis.
Purpose of the Study:
- To create fusion proteins combining CD70 antibody targeting with TRAIL-mediated apoptosis.
- To evaluate the efficacy of these fusion proteins in targeting CD70-expressing tumors.
- To develop ADCC-independent cell death-inducing agents.
Main Methods:
- Constructed fusion proteins of single-chain variable fragment (scFv) anti-CD70 antibody (lαhCD70) with TNC-TRAIL.
- Investigated fusion protein binding to CD70 and apoptosis induction.
- Introduced mutations into TRAIL to confer TRAIL receptor specificity.
Main Results:
- Fusion protein scFv:lαhCD70-TNC-TRAIL demonstrated enhanced apoptosis induction upon CD70 binding.
- The fusion protein effectively inhibited CD70-CD27 interactions.
- Engineered fusion proteins exhibited CD70-restricted, TRAIL death receptor-specific activity.
Conclusions:
- Fusion proteins of anti-CD70 scFv and TRAIL are effective in targeting CD70-expressing tumors.
- These novel agents induce apoptosis and block CD70-CD27 signaling.
- Receptor-specific TRAIL fusion proteins offer targeted cancer therapy potential.
